Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...
First-in-human study of EPI-326 will evaluate the company's lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to expand to CRC AACR 2026 presentations, including New ...
Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
A study designed to investigate why lung cancer incidence has increased among younger nonsmokers over the past few decades ...
Memorial Sloan Kettering scientists are shedding new light on a tumor’s earliest moments — revealing how lung cells with ...
In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results